I'll start by comparing the revenue growth rates of AbbVie and Sanofi, then move on to discuss how often these two leaders in the autoimmune disease treatment market beat Wall Street analysts ...

Pharmaceutical giant AbbVie has filed a lawsuit against Genmab, claiming the Denmark-based drugmaker, who is also a commercial oncology partner with the North Chicago-based company, knowingly ...

Investors with a lot of money to spend have taken a bullish stance on AbbVie ABBV. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

Whales with a lot of money to spend have taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 29 trades. If we consider the specifics of each trade ...

AbbVie’s former CEO Richard Gonzalez—who collected a $25.7 million payout for his final full year on the job in 2023—often ranked among the industry’s highest-paid CEOs during his tenure ...

Earlier this week, AbbVie ABBV announced that it is in-licensing rights to develop phase I candidate, GUB014295, a long-acting amylin analog for the treatment of obesity, from Danish research ...

Naomi Osaka may have suffered a tough loss at the Miami Open, but she is keeping her spirits high. After falling to Italy’s Jasmine Paolini in a hard-fought three-set match, Osaka took to ...

AbbVie was downgraded to "Hold" due to high debt, fluctuating earnings, and declining Humira sales, but the stock outperformed with a 31% return since July 2024. Despite mixed quarterly results ...

So, you want to invest in AbbVie (ABBV 1.21%) because it's a promising dividend-paying stock, and you also want to receive $1,000 per year in dividend income from it. How many shares should you buy?

Naomi Osaka showed that she is on the road to recovery from the abdominal injury that forced her out of the Australian Open in January, but getting sharp and match tough is going to take a little ...

The global OTC artificial tears market generated $4,379 million in 2020, and is projected to reach $6,399.43 million by 2028, growing at a CAGR of 4.94% from 2021 to 2028. Artificial tears also known ...

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing. If consummated ...